Amivantamab–Lazertinib OS Likely Year Longer Than with Osimertinib

Final data from the MARIPOSA trial of amivantamab–lazertinib versus osimertinib in initial management of EGFR-mutated non–small cell lung cancer found the combination was associated with a marked improvement in overall survival. Further analyses presented at the World Conference on Lung Cancer 2025 suggest that this could be due to altered tumor biology.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0076
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Amivantamab–Lazertinib OS Likely Year Longer Than with Osimertinib

Cancer Discovery
Lung Cancer Treatments and Mutations
article

Amivantamab–Lazertinib OS Likely Year Longer Than with Osimertinib

article en

Abstract

Final data from the MARIPOSA trial of amivantamab–lazertinib versus osimertinib in initial management of EGFR-mutated non–small cell lung cancer found the combination was associated with a marked improvement in overall survival. Further analyses presented at the World Conference on Lung Cancer 2025 suggest that this could be due to altered tumor biology.

Cancer Discovery
Openalex Percentile: Top 64%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Amivantamab–Lazertinib OS Likely Year Longer Than with Osimertinib · Cancer Discovery (2025) | TGRS Research Map | TGRS